Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in Idiopathic Pulmonary Fibrosis – Phase II
CTR20201962Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nerandomilast in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Oct 2020; status: completed.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20201962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201962.